jama naion semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy In this case series study,

Not a call center

Noboru Kurinami 1,2,3* , Masafumi Takada 1* , Seigo Sugiyama 1,4 , Akira Yoshida 1 , Kunio Hieshima 1 , Tomoko Suzuki 1 , Fumio Miyamoto 1 , Keizo Kajiwara 1 , Katsunori Jinnouchi 1 , Kenji Ashida 2 , Masatoshi Nomura 2 , Hideaki Jinnouchi 1,5 Endocrinology and Metabolism 2025;40(6):1012-1015

Semaglutide (GLP-1 agonist) Semaglutide is the most well-known weight loss peptide available, and for good reason

Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1extracellular domain (MSR1) and angiopoietin-2 (ANGPT2)